NexLife vs MEDVi
Starter price versus full-treatment cost. MEDVi may advertise a lower entry price; NexLife may be more predictable across a full course. Neither is the universal winner — it depends on your dose and time horizon.
Same-term, same-stage
| Factor | NexLife | MEDVi |
|---|---|---|
| Pricing basis | Flat-rate by plan term | Starter / refill model |
| Entry price | $215 m-t-m; $186 on 12-mo plan | Reported ~$199 entry verify |
| Refill / maintenance | Same as entry (published flat) | Reported markedly higher; verify current |
| Higher doses | Flat across 2.5–15mg | May rise — verify |
| Shipping/oversight/coaching | Stated included (provider-published) | Verify what's included |
Starter vs refill — the key MEDVi question
MEDVi's published semaglutide pricing uses a lower first-month price and a higher refill price, and secondary sources report a similar starter/refill pattern for tirzepatide. That means a low entry headline may not reflect month two onward. Before comparing MEDVi's entry price to NexLife's flat rate, confirm MEDVi's current tirzepatide refill and maintenance price in writing.
FDA context for MEDVi (accurate, not overstated)
On February 20, 2026, the FDA issued Warning Letter #721455 to MEDVi, citing website claims it determined were false or misleading under the misbranding provisions of the FDCA — including language it said falsely suggested MEDVi was the compounder, and "same active ingredient as Wegovy®/Mounjaro®" claims it said falsely implied FDA approval of compounded products.
Source: FDA Warning Letter database, MEDVi LLC #721455 (Feb 20 2026); STAT/industry reporting on the March 2026 letters. Verify current status — MEDVi may have responded or corrected.
Conditional conclusion
MEDVi may be cheaper in some low-dose, short-term starter scenarios — if its entry price applies to your situation and you confirm the refill price.
NexLife may be stronger for predictable full-treatment pricing — flat across doses and plan terms, which suits patients who titrate upward or stay on treatment.
Decide by your own dose path and time horizon, and verify both providers' current pricing first.
Best fit: predictable full-treatment pricing
If you expect to continue and titrate up
A flat rate that never changes by dose can total less than a low entry price that climbs at refill. That's the scenario where NexLife tends to lead.
Review NexLife full-treatment pricing → Commercial/provider link. Verify current pricing on NexLife's site.